Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17β-estradiol

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11147-11157

  Huang, Yong ^a,c   Fernandez, Sandra V ^b   Goodwin, Shirlean ^a   Russo, Patricia A ^b   Russo, Irma H ^b   Sutter, Thomas R ^a   Russo, Jose ^b  

^a UNIVERSITY OF MEMPHIS   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; ESTRADIOL; KERATIN; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CHROMOSOME 4; CHROMOSOME 8P; CHROMOSOME ABERRATION; CONTROLLED STUDY; EPITHELIUM CELL; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MESENCHYME CELL; PHENOTYPE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; EPITHELIUM; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MESODERM; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 37049033290     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1371     Document Type: Article

References (52)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mammary. Suggestions for new method of treatment with illustrative cases. Lancet 1896;2:104-7.
2. Boyd S. An oophorectomy in cancer of the breast. Br Med J 1900;2:1161-7.
3. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988;48:246-53.
4. Suga S, Kato K, Ohgami T, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol 2007;105:341-50.
5. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-α. Cancer Res 1999;59:1869-76.
6. Rogan EG, Badawi AF, Devanesan PD, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702.
7. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997;94:10937-42.
8. Li JJ, Li SA. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 1987;46:1858-63.
9. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-7.
10. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001;20:7945-53.
11. Fernandez SV, Russo IH, Lareef M, Balsara B, Russo J. Comparative genomic hybridization of human breast epithelial cells transformed by estrogen and its metabolites. Int J Oncol 2005;26:691-5.
12. Lareef MH, Garber J, Russo PA, et al. The estrogen antagonist ICI-182-780 does not inhibit the transformation phenotypes induced by 17-β-estradiol and 4-OH estradiol in human breast epithelial cells. Int J Oncol 2005;26:423-9.
13. Cavalieri E, Rogan E, Chakravarti D. The role of endogenous catechol quinones in the initiation of cancer and neurodegenerative diseases. Methods Enzymol 2004;382:293-319.
14. Russo J, Hasan Lareef M, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 2003;87:1-25.
15. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
16. Russo J, Gusterson BA, Rogers AE, et al. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-78.
17. Russo IH, Russo J. In vitro models for human breast cancer. In: Molecular basis of breast cancer prevention and treatment. Heidelberg: Springer-Verlag; 2004. p. 227-80.
18. Pilat MJ, Christman JK, Brooks SC. Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6. Breast Cancer Res Treat 1996;37:253-66.
19. Fernandez SV, Russo IH, Russo J. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer 2006;118:1862-8.
20. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
21. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-26.
22. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
23. Russo J, Lareef MH, Tahin Q, et al. 17β-Estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 2002;80:149-62.
24. Russo J, Fernandez SV, Russo PA, et al. 17-β-Estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 2006;20:1622-34.
25. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
26. Consortium. The Gene Ontology (GO) project in 2006. Nucleic Acids Res 2006;34:D322-6.
27. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006;5:14.
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
29. Danen EH, Yamada KM. Fibronectin, integrins, and growth control. J Cell Physiol 2001;189:1-13.
30. Fuchs IB, Lichtenegger W, Buehler H, et al. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 2002;22:3415-9.
31. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
32. Sommers CL, Heckford SE, Skerker JM, et al. Loss of epithelial markers and acquisition of vimentin expression in Adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992;52:5190-7.
33. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Phys 1997;273:F563-74.
34. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9.
35. Nollet F, Berx G, van Roy F. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun 1999;2:77-85.
36. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
37. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-8.
38. Hemavathy K, Ashraf SI, Ip YT. Snail/slug family of repressors: slowly going into the fast lane of development and cancer. Gene 2000;257:1-12.
39. Zhou BP, Deng J, Xia W, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;6:931-40.
40. Risse-Hackl G, Adamkiewicz J, Wimmel A, Schuermann M. Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins. Oncogene 1998;16:3057-68.
41. Janda E, Lehmann K, Killisch I, et al. Ras and TGF[β] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
42. Thuault S, Valcourt U, Petersen M, et al. Transforming growth factor-β employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 2006;174:175-83.
43. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005;11:8006-14.
44. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-26.
45. Roca X, Mate JL, Ariza A, et al. CD44 isoform expression follows two alternative splicing pathways in breast tissue. Am J Pathol 1998;153:183-90.
46. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992;118:971-7.
47. Droll A, Dougherty ST, Chiu RK, et al. Adhesive interactions between alternatively spliced CD44 isoforms. J Biol Chem 1995;270:11567-73.
48. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004;64:64-71.
49. Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004;64:8541-9.
50. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
51. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
52. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.